News

Patients who received diroximel fumarate experienced statistically significantly fewer number of days of key gastrointestinal symptoms with intensity scores ≥2 on the IGISIS compared to those on dimethyl fumarate.

The FDA has assigned the application a PDUFA target action date of March 17, 2020.

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne discussed the early-stage research into neurorehabilitation post-epilepsy surgery, and the promise it might hold to address surgery’s long-term risks.

One year post-launch, the Ambry Genetics and Akcea Therapeutics hereditary ATTR amyloidosis testing program has been used by more than 700 physicians. The free test screens for up to 81 genes that cause hereditary polyneuropathies and up to 92 genes associated with hereditary cardiomyopathies, including hATTR amyloidosis.

After its recent FDA clearance, the smartphone-controlled Nerivio Migra makes its entrance into the market in the fall. Theranica’s CEO and co-founder spoke to its clinical efficacy and advantages for patients and physicians.

On our anniversary, take a look back at some of our most popular articles and interviews across a range of neurology topics.

Early focal inflammatory disease activity and spinal cord lesions are predictors of long-term disease outcomes, which may be useful in counseling patients and personalizing treatment plans.

At usual-speed walking, a number of domains of gait variability, pace, asymmetry, and postural control were significantly predictive of conversion to Parkinson disease, and could be used in combination with markers to identify prodromal disease and its progression.

Investigators found reductions in tic frequency and increases in the number of tic-free intervals when children were merely asked verbally to suppress their tics, and when an immediate and contingent reward was delivered for successful tic suppression, tic suppression was enhanced.

The use of single-pulse transcranial magnetic stimulation, while already FDA-approved for acute and preventive migraine treatment, has shown that it can be effective in reducing the need for acute headache medications in patients with migraine.

The clinical professor of neurology at Albert Einstein College of Medicine spoke to the findings of the OVERCOME study, and how recent literature has suggested that improper prescriptions and medication use in migraine have been ongoing in spite of the current recommendations.

Zogenix has announced that its Study 1601 of fenfluramine (Fintepla), also known as ZX008, in the treatment of seizures associated with Lennox-Gastaut syndrome has completed enrollment and is on schedule to report top-line data in Q1 2020.

Despite the fact that the rate of reductions for recurrent stroke in the intensive group were not significant in this study, a meta-analysis of 3 previous trials supports the use of a blood pressure target less than 130/80 mm Hg to reduce stroke recurrence.

The co-director of the University of Pennsylvania Memory Center will share additional insights on Alzheimer disease at the upcoming International Congress on the Future of Neurology, taking place September 27-28, 2019 in New York City.

The director of the MedStar Georgetown Headache Center discussed the barriers to patient and clinician education in migraine and the gap in available interventions for the diverse patient population.

The University of Alabama at Birmingham neuromodulation epilepsy clinic has treated 43 patients with drug-resistant epilepsy, reducing seizures by >60% for a number of patients with both vagus nerve stimulation and responsive neurostimulation techniques.

The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair of the department of brain health at the University of Nevada Las Vegas spoke about therapies under investigation for the treatment of agitation and psychosis in Alzheimer disease.

The co-director of the Gates Stroke Center and Cerebrovascular Surgery at Kaleida Health and director of endovascular stroke treatment and research medical director of neuroendovascular services at Gates Vascular Institute spoke about unmet needs in stroke and the value of introducing innovative technologies into the space.

The Drowzle algorithm was tested against polysomnography results and provided a sensitivity of 93.7% to detect moderate and severe obstructive sleep apnea.

The PKG wearable was able to more effectively and objectively assess motor fluctuations in patients with Parkinson disease than standard patient-reported motor diaries.

Though no details have been reported, Janssen Pharmaceuticals announced that its S1P modulator ponesimod has met its primary and key secondary end points in the OPTIMUM study, in which it was compared to teriflunomide in patients with relapsing MS.

The investigators noted that these data provide robust and promising evidence that eptinezumab is associated with a rapid preventive effect in chronic migraine that is sustained for 3 months after a single infusion.

The professor and chief of pediatric neurology at Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center discussed the decision-making process for choosing interventions for patients with epilepsy, and how to keep patients adherent.

Your patient asks if a ketogenic diet can reduce her migraines. What will you tell her?

The chief medical officer of electroCore discussed the various data which have been published on the use of noninvasive vagus nerve stimulation in different populations of patients with migraine and headache.

The investigational therapy has the potential to be a first-in-class neuronal progenitor cell therapeutic with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in stroke.

The director of headache medicine and chief of general neurology at Yale Medicine discussed the long-term success the new preventive migraine therapies have shown thus far, and how the lack of safety concerns will improve how they’re utilized.

Despite previous case series suggesting that undergoing surgery may increase the risk of multiple sclerosis relapse, retrospective analysis of more than 600 surgeries undergone by patients with progressive and relapsing MS now proposes that the risk of relapse is not high in the postoperative period.